MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

LON:CIRCircassia Pharmaceuticals Share Price, Forecast & News

GBX 25
+0.40 (+1.63 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
24
Now: GBX 25
25.75
50-Day Range
17.50
MA: GBX 25.35
28
52-Week Range
0.26
Now: GBX 25
29.95
Volume906,992 shs
Average VolumeN/A
Market Capitalization£93.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. The company has a collaboration agreement with AstraZeneca to promote Tudorza and for COPD treatment, and has the United States commercial rights to COPD therapy Duaklir. It markets its products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners in China, Japan, Europe, and internationally. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Read More
Circassia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.11 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone44 1865 405 560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£47.80 million
Cash FlowGBX 5.69 per share
Book ValueGBX 27.70 per share

Profitability

Miscellaneous

Employees400
Market Cap£93.80 million
Next Earnings DateN/A
OptionableOptionable

Receive CIR News and Ratings via Email

Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter.

Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions

How has Circassia Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Circassia Pharmaceuticals' stock was trading at GBX 19.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CIR shares have increased by 27.2% and is now trading at GBX 25. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Circassia Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Circassia Pharmaceuticals.

What price target have analysts set for CIR?

1 Wall Street analysts have issued twelve-month price objectives for Circassia Pharmaceuticals' shares. Their forecasts range from GBX 70 to GBX 80. On average, they anticipate Circassia Pharmaceuticals' share price to reach GBX 73.33 in the next year. This suggests a possible upside of 193.3% from the stock's current price. View analysts' price targets for Circassia Pharmaceuticals.

Has Circassia Pharmaceuticals been receiving favorable news coverage?

News headlines about CIR stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Circassia Pharmaceuticals earned a news impact score of -5.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCircassia Pharmaceuticals.

Who are some of Circassia Pharmaceuticals' key competitors?

What other stocks do shareholders of Circassia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Circassia Pharmaceuticals investors own include Enquest (ENQ), BOOHOO GRP PLC/ADR (BHOOY), Cummins (CMI), FutureFuel (FF), Trade Desk (TTD), Ascential (ASCL), H&T Group (HAT), Howden Joinery Group (HWDN), NMC Health (NMC) and Sirius Minerals (SXX).

Who are Circassia Pharmaceuticals' key executives?

Circassia Pharmaceuticals' management team includes the following people:
  • Mr. Steven Charles Andrew Harris, Co-Founder, CEO & Director (Age 52)
  • Mr. Julien Cotta, CFO, Company Sec. & Director (Age 55)
  • Dr. Roderick Peter Hafner, Sr. VP of R&D and Director (Age 53)
  • Ms. Nina Kataria, Sr. VP Global HR
  • Mr. David L. Acheson, Sr. VP of US Commercial

What is Circassia Pharmaceuticals' stock symbol?

Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR."

How do I buy shares of Circassia Pharmaceuticals?

Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Circassia Pharmaceuticals' stock price today?

One share of CIR stock can currently be purchased for approximately GBX 25.

How big of a company is Circassia Pharmaceuticals?

Circassia Pharmaceuticals has a market capitalization of £93.80 million and generates £47.80 million in revenue each year. Circassia Pharmaceuticals employs 400 workers across the globe.

What is Circassia Pharmaceuticals' official website?

The official website for Circassia Pharmaceuticals is www.circassia.co.uk.

How can I contact Circassia Pharmaceuticals?

The company can be reached via phone at 44 1865 405 560.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.